MX2017005883A - Administracion oral de farmacos inestables o deficientemente absorbidos. - Google Patents
Administracion oral de farmacos inestables o deficientemente absorbidos.Info
- Publication number
- MX2017005883A MX2017005883A MX2017005883A MX2017005883A MX2017005883A MX 2017005883 A MX2017005883 A MX 2017005883A MX 2017005883 A MX2017005883 A MX 2017005883A MX 2017005883 A MX2017005883 A MX 2017005883A MX 2017005883 A MX2017005883 A MX 2017005883A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage forms
- oral administration
- drug
- poorly
- unstable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La descripción se relaciona a una forma de dosificación y combinaciones de formas de dosificación útiles para administración oral eficaz de fármacos que de otro modo no son adecuados para administración oral, degradación debido al ácido y/o mediada por proteasa. Las formas de dosificación incluyen un sistema de administración de fármaco auto-micro emulsionante (SMEDDS) al cual se combina el fármaco y un antiácido. Cuando se co-administra al mamífero, las formas de dosificación pueden prevenir degradación del fármaco mediante el ácido fuerte y enzimas digestivas normalmente presentes en un entorno gástrico, y pueden mejorar la absorción de fármacos soluble en agua en el tracto gastrointestinal (GI). Las formas de dosificación se pueden usar para administrar de manera eficaz insulina por una vía oral, por ejemplo, tal como en la forma de un polvo que se puede almacenar durante largos periodos y reconstituirse con agua u otro fluido poco antes de la administración.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462075144P | 2014-11-04 | 2014-11-04 | |
US201562197286P | 2015-07-27 | 2015-07-27 | |
PCT/IB2015/002181 WO2016071756A1 (en) | 2014-11-04 | 2015-11-04 | Oral administration of unstable or poorly-absorbed drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017005883A true MX2017005883A (es) | 2017-11-28 |
Family
ID=55908656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017005883A MX2017005883A (es) | 2014-11-04 | 2015-11-04 | Administracion oral de farmacos inestables o deficientemente absorbidos. |
Country Status (15)
Country | Link |
---|---|
US (2) | US11331376B2 (es) |
EP (1) | EP3215128B1 (es) |
JP (1) | JP6797115B2 (es) |
KR (1) | KR102502308B1 (es) |
CN (1) | CN107205928B (es) |
AU (1) | AU2015341479B2 (es) |
CA (1) | CA2966619C (es) |
ES (1) | ES2759004T3 (es) |
IL (1) | IL252080B (es) |
MX (1) | MX2017005883A (es) |
MY (1) | MY194945A (es) |
RU (1) | RU2746548C2 (es) |
SG (1) | SG11201703593PA (es) |
TW (1) | TWI728959B (es) |
WO (1) | WO2016071756A1 (es) |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3591680A (en) * | 1969-11-17 | 1971-07-06 | Smith Kline French Lab | Concentrated antacid compositions and method of producing antacid activity |
US4327076A (en) | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
WO1999033489A1 (fr) | 1997-12-26 | 1999-07-08 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicinales a liberation prolongee |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6656701B2 (en) | 1999-07-16 | 2003-12-02 | Actim Organics, Inc | Combination of acid protease enzymes and acidic buffers and uses thereof |
CN1160122C (zh) * | 2001-04-20 | 2004-08-04 | 清华大学 | 一种制备口服胰岛素油相制剂的方法 |
EE200400024A (et) | 2001-06-21 | 2004-06-15 | Pfizer Products Inc. | Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid |
UY28057A1 (es) * | 2002-10-31 | 2003-12-31 | Alza Corp | Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrófobos |
US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
ZA200805646B (en) * | 2005-12-28 | 2009-12-30 | Takeda Pharmaceutical | Controlled release solid preparation |
ZA200805706B (en) * | 2005-12-28 | 2010-02-24 | Takeda Pharmaceutical | Controlled release solid preparation |
PL2197429T3 (pl) | 2007-09-03 | 2016-09-30 | Kompozycje w postaci cząstek do dostarczania słabo rozpuszczalnych leków | |
US20090130198A1 (en) * | 2007-11-21 | 2009-05-21 | Innopharmax Inc. | Pharmaceutical composition with enhanced bioavailability |
FR2925333B1 (fr) * | 2007-12-19 | 2012-04-13 | Farid Bennis | Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives |
US20110293714A1 (en) | 2008-11-28 | 2011-12-01 | Novo Nordisk A/S | Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides |
US20100273730A1 (en) * | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
EP2523655A2 (en) | 2010-01-12 | 2012-11-21 | Novo Nordisk A/S | Pharmaceutical compositions for oral administration of insulin peptides |
PL2651415T3 (pl) * | 2010-12-13 | 2021-04-19 | Rite-Prep Pty Ltd. | Formulacje dożołądkowe i dookrężnicze oraz sposoby ich wytwarzania i zastosowania |
US20120213855A1 (en) * | 2011-02-17 | 2012-08-23 | Cima Labs Inc. | Dosage forms for weakly ionizable compounds |
US20140127296A1 (en) | 2012-11-05 | 2014-05-08 | Kenneth John Tibbs | Pharmaceutical preparation and method for treatment of diabetes |
-
2015
- 2015-11-04 TW TW104136476A patent/TWI728959B/zh active
- 2015-11-04 ES ES15856347T patent/ES2759004T3/es active Active
- 2015-11-04 KR KR1020177015249A patent/KR102502308B1/ko active IP Right Grant
- 2015-11-04 EP EP15856347.8A patent/EP3215128B1/en active Active
- 2015-11-04 US US15/524,164 patent/US11331376B2/en active Active
- 2015-11-04 JP JP2017524024A patent/JP6797115B2/ja active Active
- 2015-11-04 CA CA2966619A patent/CA2966619C/en active Active
- 2015-11-04 CN CN201580060031.9A patent/CN107205928B/zh active Active
- 2015-11-04 MY MYPI2017701545A patent/MY194945A/en unknown
- 2015-11-04 MX MX2017005883A patent/MX2017005883A/es unknown
- 2015-11-04 AU AU2015341479A patent/AU2015341479B2/en active Active
- 2015-11-04 WO PCT/IB2015/002181 patent/WO2016071756A1/en active Application Filing
- 2015-11-04 SG SG11201703593PA patent/SG11201703593PA/en unknown
- 2015-11-04 RU RU2017119212A patent/RU2746548C2/ru active
-
2017
- 2017-05-03 IL IL252080A patent/IL252080B/en active IP Right Grant
-
2022
- 2022-04-13 US US17/719,969 patent/US20220233649A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2015341479B2 (en) | 2020-11-26 |
RU2746548C2 (ru) | 2021-04-15 |
MY194945A (en) | 2022-12-27 |
RU2017119212A (ru) | 2018-12-05 |
KR102502308B1 (ko) | 2023-02-21 |
TWI728959B (zh) | 2021-06-01 |
KR20170099881A (ko) | 2017-09-01 |
TW201632172A (zh) | 2016-09-16 |
IL252080A0 (en) | 2017-07-31 |
EP3215128A4 (en) | 2017-11-29 |
IL252080B (en) | 2021-03-25 |
RU2017119212A3 (es) | 2019-05-24 |
CA2966619A1 (en) | 2016-05-12 |
US20220233649A1 (en) | 2022-07-28 |
US11331376B2 (en) | 2022-05-17 |
SG11201703593PA (en) | 2017-06-29 |
CN107205928A (zh) | 2017-09-26 |
CA2966619C (en) | 2023-03-14 |
ES2759004T3 (es) | 2020-05-07 |
BR112017009326A2 (pt) | 2017-12-19 |
WO2016071756A1 (en) | 2016-05-12 |
EP3215128B1 (en) | 2019-09-04 |
EP3215128A1 (en) | 2017-09-13 |
AU2015341479A1 (en) | 2017-06-15 |
JP2017533239A (ja) | 2017-11-09 |
JP6797115B2 (ja) | 2020-12-09 |
US20170360894A1 (en) | 2017-12-21 |
CN107205928B (zh) | 2021-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4233978A3 (en) | Oral delivery of active drug substances | |
MX2023000320A (es) | Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion. | |
MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
MX340822B (es) | Formulaciones para suministro oral de adsorbentes en el intestino. | |
NZ704584A (en) | Liquid stable virus vaccines | |
WO2011112229A3 (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
IN2014CN00338A (es) | ||
MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
IN2014DN06737A (es) | ||
PH12014502191A1 (en) | Capsule disintegrable in large-intestine-specific manner | |
PH12017501084A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
WO2014044794A3 (en) | Pharmaceutical composition | |
PL3793534T3 (pl) | Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego | |
EA201591188A1 (ru) | Доставка глатирамера ацетата через слизистую оболочку | |
MX2017015202A (es) | Formulaciones liquidas de celecoxib para administracion oral. | |
MX2016010892A (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica. | |
MX2017005883A (es) | Administracion oral de farmacos inestables o deficientemente absorbidos. | |
PH12014501822A1 (en) | Oral formulation comprising lansoprazole and the preparation method thereof | |
NZ707033A (en) | Dispersible nimorazole tablet | |
EA201790089A1 (ru) | Фармацевтические средства для лечения головокружения различной этиологии | |
SA515360445B1 (ar) | قرص قابل للتشتيت | |
MX2019001399A (es) | Formulacion de calcitonina estable a temperatura ambiente para la via oral. | |
DK201270714A (en) | Dispersible tablet | |
TH167686B (th) | สารตัวยาแบบผสมผสานซึ่งประกอบรวมด้วยเฟนิเลฟรีนและพาราเซตามอล |